Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests

Executive Summary

Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas

You may also be interested in...



Singulex’ Cardiac Troponin Test Predicts Cardiac Risk In Stable Patients

Results of from a new analysis of plasma samples from an old statin trial suggest that Singulex’ high-sensitivity cardiac troponin test can track the cardiovascular risk in stable patients with ischemic heart disease.

Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed

Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin

Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed

Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel